Member Login About NKF Recursos en Español

Search

Displaying 1 - 10 of 262

Company recognized for developing the first-of-its-kind program designed to support employees, and boost the critically low number of living donor organ transplants

January 27, 2021, New York, NY — UnitedHealth Group has been selected to receive the 2021 Corporate Innovator Award from the National Kidney Foundation (NKF) as part of the annual Spring Clinical Meetings...
  Keryx Biopharmaceuticals recognized for iron deficiency anemia treatment approved for early-stage chronic kidney disease patients   New York, NY—April 3, 2018—Keryx Biopharmaceuticals has been selected to receive the 2018 Corporate Innovator Award from the National Kidney Foundation (NKF) at its 27th annual Spring Clinical Meetings in Austin, Texas. In November 2017, Keryx Biopharmaceutical’s received expanded FDA approval of...
Company recognized for developing the first new treatment for diabetic kidney disease (DKD) to be approved by the FDA in nearly two decades.   March 20, 2020, New York, NY —Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson has been selected to receive the 2020 Corporate Innovator Award from the National Kidney Foundation (NKF) as part of the annual ...
  Company recognized for treatment recently approved in the U.S. for adults at risk of rapidly progressing Autosomal Dominant Polycystic Kidney Disease   New York, NY — May 2, 2019 – Otsuka Pharmaceutical Company, Ltd. has been selected to receive the 2019 Corporate Innovator Award from the National Kidney Foundation (NKF) at the 2019 Spring Clinical Meetings in Boston.   In April 2018, Otsuka’s JYNARQUETM (...

Startup Company Developing Proprietary Process to Reset the Clock on Donated Kidneys

October 24, New York, NY —The National Kidney Foundation (NKF) Innovation Fund, the philanthropic impact investment program of NKF, today announced a new investment that could have a major impact in kidney transplantation in the United States. 34 Lives, formerly Renovera, has received an investment from NKF to accelerate the development of a...

~ Collaboration aims to revolutionize kidney transplantation outcomes by liberating patients from immunosuppressive medications. ~

 

(New York, NY, January 30, 2024) – The National Kidney Foundation (NKF) announced today its latest strategic investment through its NKF Innovation Fund. The fund will support ImmunoFree, a pioneering biomedical...

We are looking for committed volunteers to join us at our annual NKF Corporate Monopoly Tournament!

~Collaboration aims to transform kidney transplantation and enhance health equity~

 

(September 21, 2023, New York, NY) – The National Kidney Foundation (NKF) is proud to announce its latest investment through the NKF Innovation Fund, which is aimed at fostering innovation and advancing kidney health. NKF has chosen to invest in...

~ Collaboration aims to improve kidney transplantation and enhance health equity ~

(New York, NY (November 16, 2023) – The National Kidney Foundation (NKF) is proud to announce its latest investment through the NKF Innovation Fund. ZeitLife™ Transplant Innovations, Inc., is a global medical device company specializing in advancing technologies to modernize kidney preservation and logistics.

Led by industry...

June 12, 2023, New York, NY —The National Kidney Foundation (NKF) is proud to announce its latest investment through the NKF's Innovation Fund in Klinrisk, an artificial intelligence-based medical device company. Klinrisk is dedicated to transforming the early identification and management of high-risk chronic kidney disease (CKD) through accurate clinical risk prediction and decision support.

...

30 East 33rd Street, New York, NY 10016

© 2024 National Kidney Foundation Inc.